Manufacturing and Facilities eBook
Read the article: A Look at Supply Chain for Scale Up
Read the eBook: BioPharm International’s Manufacturing and Facilities 2023 eBook
Taking a brief status check on the biologics supply chain and any impact on scale up operations.
In speaking with Suzanne Aldington, senior principal scientist, Downstream Processing, Biologics, and Lucas Lin, senior principal scientist, Global Process Development Implementation, Biologics, both at Lonza, BioPharm International® took a pulse on the supply chain lifeline for biologics in the post-pandemic setting. Discussion revolved around any impact the current state of the supply chain may be imparting on scale-up activities in downstream bioprocessing.
Read this article in BioPharm International®’s Manufacturing and Facilities 2023 eBook.
Read the article: A Look at Supply Chain for Scale Up
Read the eBook: BioPharm International’s Manufacturing and Facilities 2023 eBook
Feliza Mirasol is the science editor for BioPharm International.
BioPharm International
eBook: Manufacturing and Facilities 2023
November 2023
Page: 12
When referring to this article, please cite it as Mirasol, F. A Look at Supply Chain for Scale Up. BioPharm International’s Manufacturing and Facilities 2023 eBook. November 2023.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.